[The effect of the synthetic immunomodulator thymogen on radiation-induced carcinogenesis in rats].
Anisimov. V N VN; Miretskiĭ. G I GI; Morozov. V G VG; Pavel'eva. I A IA; Khavinson. V Kh VKh
Key Findings
- Thymogen reduced the overall number of tumors and breast adenocarcinomas caused by Sr‑90 and Cs‑137 exposure.
- Rats treated with thymogen alone showed a modest increase in lifespan and a slower aging rate.
- The study is the first to show that this synthetic immunomodulating peptide can inhibit both radiation‑induced and spontaneous cancer in female rats.
Practical Outcomes
- For DIY health enthusiasts, the data suggest thymogen might have anti‑cancer and longevity‑supporting properties, but the evidence is limited to rodents and high‑dose, short‑term regimens. Until human trials are available, it’s not ready for direct self‑administration, though it highlights the potential of immune‑modulating peptides as a research area for future anti‑aging protocols.
Summary
In a rat study, a synthetic peptide called thymogen was given once a month for five days. The rats that got thymogen had fewer cancers caused by radioactive chemicals and lived longer with fewer age‑related tumors. The peptide also seemed to protect against spontaneous cancers when given by itself.
Abstract
Five month-old female rats were given a mixture of Sr-90 and Cs-137 in drinking water in the dose of 0.1 and 0.2 microCi/day per animal over 12 months. Some animals received 12 monthly courses of a synthetic immunomodulating dipeptide--thymogen in the dose of 5 micrograms/animal for 5 consecutive days. Radionuclide-treated rats showed higher occurrence of tumors on the whole and of breast adenocarcinoma, in particular. Thymogen was shown to inhibit Sr-90- and Cs-137-induced radiation carcinogenesis, namely, a decrease in the total tumor and cancer occurrence was observed. The animals receiving thymogen alone showed longer life span, slower rate of aging and lower overall tumor and cancer occurrence. In this study, the ability of a synthetic peptide immunomodulator--thymogen to inhibit spontaneous and radionuclide-induced carcinogenesis in female rats was first established.
Study Information
pubmed
1992